These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Erhardt L; MacLean A; Ilgenfritz J; Gelperin K; Blumenthal M Eur Heart J; 1995 Dec; 16(12):1892-9. PubMed ID: 8682023 [TBL] [Abstract][Full Text] [Related]
3. Effect of angiotensin converting enzyme inhibition on plasma endothelin in congestive heart failure. Townend J; Doran J; Jones S; Davies M Int J Cardiol; 1994 Mar; 43(3):299-304. PubMed ID: 8181887 [TBL] [Abstract][Full Text] [Related]
4. Reversal of peripheral microvascular dysfunction during long-term treatment with the angiotensin-converting enzyme inhibitor fosinopril in congestive heart failure. Galatius S; Wroblewski H; Sørensen V; Haunsø S; Nørgaard T; Kastrup J J Card Fail; 1999 Mar; 5(1):17-24. PubMed ID: 10194656 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the first dose response of fosinopril and captopril in congestive heart failure: a randomized, double-blind, placebo controlled study. Eryonucu B; Koldas L; Ayan F; Keser N; Sirmaci A Jpn Heart J; 2001 Mar; 42(2):185-91. PubMed ID: 11384079 [TBL] [Abstract][Full Text] [Related]
6. [Effect of fosinopril on the rate of neurohumoral and proinflammatory activation in patients with heart failure]. Berezin AE Klin Med (Mosk); 2004; 82(9):29-32. PubMed ID: 15540418 [TBL] [Abstract][Full Text] [Related]
7. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? MacFadyen RJ; Lee AF; Morton JJ; Pringle SD; Struthers AD Heart; 1999 Jul; 82(1):57-61. PubMed ID: 10377310 [TBL] [Abstract][Full Text] [Related]
8. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Fosinopril Heart Failure Study Group. Brown EJ; Chew PH; MacLean A; Gelperin K; Ilgenfritz JP; Blumenthal M Am J Cardiol; 1995 Mar; 75(8):596-600. PubMed ID: 7887385 [TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Cesari M; Kritchevsky SB; Atkinson HH; Penninx BW; Di Bari M; Tracy RP; Pahor M Am Heart J; 2009 Feb; 157(2):334.e1-8. PubMed ID: 19185642 [TBL] [Abstract][Full Text] [Related]
10. Treatment of congestive heart failure: experience with fosinopril. Blumenthal M Am J Hypertens; 1997 Oct; 10(10 Pt 2):289S-298S. PubMed ID: 9366286 [TBL] [Abstract][Full Text] [Related]
11. Increased plasma concentrations of endothelin in congestive heart failure in humans. Rodeheffer RJ; Lerman A; Heublein DM; Burnett JC Mayo Clin Proc; 1992 Aug; 67(8):719-24. PubMed ID: 1434909 [TBL] [Abstract][Full Text] [Related]
12. Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure. Pacher R; Stanek B; Globits S; Berger R; Hülsmann M; Wutte M; Frey B; Schuller M; Hartter E; Ogris E Eur Heart J; 1996 Aug; 17(8):1223-32. PubMed ID: 8869864 [TBL] [Abstract][Full Text] [Related]
13. [Head-to-head comparison of clinical, biochemical and functional effects of fosinopril and enalapril in patients with systolic heart failure]. Otasević P; Putiniković B; Vukajlović Z; Ilisić B; Nesković AN Med Pregl; 2006; 59(1-2):51-6. PubMed ID: 17068892 [TBL] [Abstract][Full Text] [Related]
14. Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure. Davis R; Coukell A; McTavish D Drugs; 1997 Jul; 54(1):103-16. PubMed ID: 9211084 [TBL] [Abstract][Full Text] [Related]
15. Plasma levels of endothelin-1 at rest and after exercise in patients with moderate congestive heart failure. de Groote P; Millaire A; Racadot A; Decoulx E; Ducloux G Int J Cardiol; 1995 Oct; 51(3):267-72. PubMed ID: 8586475 [TBL] [Abstract][Full Text] [Related]
16. Treatment of heart failure with fosinopril: an angiotensin converting enzyme inhibitor with a dual and compensatory route of excretion. Mancia G; Giannattasio C; Grassi G Am J Hypertens; 1997 Oct; 10(10 Pt 2):236S-241S. PubMed ID: 9366279 [TBL] [Abstract][Full Text] [Related]
17. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency. Tong PC; Ko GT; Chan WB; Ma RC; So WY; Lo MK; Lee KF; Ozaki R; Chow CC; Cockram CS; Chan JC Diabetes Obes Metab; 2006 May; 8(3):342-7. PubMed ID: 16634995 [TBL] [Abstract][Full Text] [Related]
18. Effects of atenolol as add-on therapy to fosinopril in heart failure. Pacher R; Hülsmann M; Berger R; Koller-Strametz J; Kos T; Frey B; Dukat A; Stanek B Wien Klin Wochenschr; 1997 Apr; 109(7):232-8. PubMed ID: 9141231 [TBL] [Abstract][Full Text] [Related]
19. Captopril does not acutely modulate plasma endothelin-1 concentration in human congestive heart failure. Grenier O; Pousset F; Isnard R; Kalotka H; Carayon A; Maistre G; Lechat P; Guerot C; Thomas D; Komajda M Cardiovasc Drugs Ther; 1996 Nov; 10(5):561-5. PubMed ID: 8950071 [TBL] [Abstract][Full Text] [Related]
20. Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in Heart Failure Study Investigators. Zannad F; Chati Z; Guest M; Plat F Am Heart J; 1998 Oct; 136(4 Pt 1):672-80. PubMed ID: 9778071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]